Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients

NCT02269176 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02269176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02269176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2000
Completion date
Not reported
Enrollment
330 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension